181-195 of 379
Moving Beyond Immunosuppressive Therapy in IgAN
Clinician's RoundtableMoving Beyond Immunosuppressive Therapy in IgAN
Gates B. Colbert, MD
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Charles Turck, PharmD, BCPS, BCCCP
Jonathon B. Cohen, MD, MS
Examining Barriers and Facilitators in Pediatric Sickle Cell Disease Care
Project Oncology®Examining Barriers and Facilitators in Pediatric Sickle Cell Disease Care
Ashley Baker, MSN, PMHNP
Alyssa Schlenz
Shannon Phillps
Differentiating and Diagnosing Sjögren’s-Related Dry Eye
Living RheumDifferentiating and Diagnosing Sjögren’s-Related Dry Eye
Michelle Hessen, OD
Sjögren’s-Related Dry Eye: Examining Targeted Treatment Strategies
Living RheumSjögren’s-Related Dry Eye: Examining Targeted Treatment Strategies
Michelle Hessen, OD
Targeting CD19 in Autoimmune Neuropathy: Case Report Insights
Living RheumTargeting CD19 in Autoimmune Neuropathy: Case Report Insights
- advertisement
Reimagining Autoimmune Care with CAR-Based Cell Therapies
Living RheumReimagining Autoimmune Care with CAR-Based Cell Therapies
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Marlene Mimi Maeusli, PhD.
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
John Cho, MD, PhD, FRCPC
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Balazs Halmos, MD, MS
- advertisement
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Balazs Halmos, MD, MS
Epithelial Cell Activation in Sjögren’s: A New Target in Chronic Inflammation
Living RheumEpithelial Cell Activation in Sjögren’s: A New Target in Chronic Inflammation
Ryan Quigley
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiersASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context